BUZZ-Oppenheimer initiates coverage on MBX Biosciences with 'outperform'

Reuters
16 Jul
BUZZ-Oppenheimer initiates coverage on <a href="https://laohu8.com/S/MBX">MBX Biosciences</a> with 'outperform'

** Brokerage Oppenheimer initiates coverage on biotech firm MBX Biosciences MBX.O with PT of $38 and "outperform" rating

** "Our enthusiasm stems from the company's innovative Precision Endocrine Peptide $(PEP)$ platform and its potential to redefine standards in endocrine and metabolic disease treatment," says Oppenheimer

** Brokerage sees its mid-stage experimental treatment, canvuparatide, for hypoparathyroidism as a "key catalyst" for this quarter

** New price target represents a 183.6% upside to the stock's last close

** Brokerage believes co's "lead candidate canvuparatide's once-weekly injections and potentially favorable efficacy to the current daily injectable standard could make it best-in-class—supporting ~$2 billion global peak sales opportunity"

** Brokerage says co's another mid-stage drug, imapextide, which is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, could be more than a $1 billion opportunity

** All five brokerages rate the stock "buy" or higher; their median PT is $38 - data compiled by LSEG

** Up to last close, stock was down 27.3% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10